Alterity Therapeutics Limited

NASDAQ:ATHE

Biotechnology

Healthcare
$3.12 +9.89%

+$0.53 today

Market cap
$52.77M
Beta
-0.03
P/E (TTM)
-9.9
EPS (TTM)
-$0.07
52W Low $2.66High $7.00

Volume 0.02M

Average 0.05M

ATHE Operating Cash Flow

Cash generated by the company's core business operations during the period.

Alterity Therapeutics LimitedNASDAQ: ATHE

Operating Cash Flow · Q2 FY2026 · quarter ended Dec 2025

Operating cash flow grows 24.7% year over year

Q2 FY2026 operating cash flow of A$10.43M (cash outflow) rose 24.7% year over year. Over 3 fiscal years it compounded at -2.5% a year.

Context

  • Operating cash flow amounted to 210.5% of revenue in FY2025, down 103.1 pp from a year earlier.
  • Operating cash flow grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
-A$10.43M— QoQ
Last fiscal yearJun 2025
-A$11.45M-9.2% YoY
Operating Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+24.7%——
1 year-9.2%——
3-year CAGR-2.5%——
5-year CAGR——
10-year CAGR——

Operating Cash Flow history

AUD · from the cash flow

Latest · FY2025
(11.45M) AUD
Year-over-year change
+9.2%

Operating Cash Flow vs competitors

How ATHE compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -9.2% is the lowest of 4, against a peer median of +18.8%.
  • Operating cash flow amounts to 210.5% of revenue for ATHE, versus a peer median of 192.1%.
ATHE Competitors
Operating Cash Flow for ATHE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ANVSAnnovis Bio, Inc.LTM Mar 2026$26.53M USD+15.6%+1039.6%—
MAIAMAIA Biotechnology, Inc.LTM Mar 2026$19.95M USD+22.3%+15.9%—
ATHEAlterity Therapeutics LimitedFY2025A$11.45M AUD-9.2%-2.5%210.5%
DYAIDyadic International, Inc.LTM Mar 2026$5.72M USD+18.8%-11.0%192.1%
Peer median (excluding ATHE) —+18.8%+15.9%192.1%

Competitors are the stored peer set for ATHE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

AUD
Metric
FY2021
Jun 2021
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
Net Income(15.31M)(12.85M)(13.81M)(19.12M)(12.15M)
Depreciation & Amortization75.37K54.21K102.26K147.53K139.72K
Deferred Income Tax2.33M(1.06M)2.99M00
Stock-Based Compensation1.88M1.51M966.57K881.95K979.92K
Change in Working Capital(4.22M)(447.68K)(3.94M)5.75M(613.68K)
Accounts Receivables(4.22M)(447.68K)(3.94M)4.62M104.07K
Inventory191.13K(2.21M)2.45M00
Accounts Payables432.91K2.6M(1.56M)1.1M0
Other Working Capital(624.03K)(393.29K)(889.52K)23.05K(717.75K)
Other Non-Cash Items(2.1M)455.57K(6.35M)(261.15K)190.62K
Operating Cash Flow(17.33M)(12.34M)(20.04M)(12.61M)(11.45M)
Capital Expenditures(10.47K)(89.15K)(7.31K)(5.72K)3
Acquisitions (Net)00000
Purchases of Investments0000(7.5M)
Sales of Investments00000
Other Investing Activities00(29.15K)00
Investing Cash Flow(10.47K)(89.15K)(36.46K)(5.72K)(7.5M)
Debt Repayment(58.29K)(34.51K)(59.92K)(10.37K)(127.1K)
Common Stock Issued39.24M17.18M316.68K10.14M42.57M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(2.49M)(836.97K)(132.41K)(918.02K)(2.77M)
Financing Cash Flow36.69M16.3M124.34K9.22M39.67M
Effect of Forex Changes(426.78K)2.81M914.94K260.36K(198.38K)
Net Change in Cash18.92M6.69M(19.03M)(3.13M)20.52M
Free Cash Flow(17.34M)(12.43M)(20.04M)(12.61M)(11.45M)

Alterity Therapeutics Limited

NASDAQ:ATHE

Intrinsic Alpha fair value

Locked

Current Price

$3.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.